1 results match your criteria: "S.Orsola-Malpighi University Hospital and Alma Mater University of Bologna[Affiliation]"
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report.
Transl Oncol
January 2019
Department of Experimental, Diagnostic and Specialty Medicine DIMES - University of Bologna, Via Massarenti 9, 40138, Bologna, Italy; Medical Oncology, S.Orsola-Malpighi University Hospital and Alma Mater University of Bologna, Via Massarenti 9, 40138, Bologna, Italy.
Introduction: Translocations of the anaplastic lymphoma kinase (ALK) can be effectively targeted in advanced non-small cell lung cancer by ALK-TKI inhibitors including Crizotinib. However, the development of acquired resistance often limits the duration of these therapies. While several mechanisms of secondary resistance have been already identified, little is known about molecular determinants of primary resistance.
View Article and Find Full Text PDF